Start with the decision in mind

• Tell me about the specific technology gap on your roadmap that led you to consider licensing university IP now.
• How does this capability change what your team can deliver over the next three years, in concrete product or program terms?
• Who on your team will be the ultimate decision maker for a license versus building internally, and who else must influence that call? Options: VP of R&D, CTO, Head of Product, Legal/General Counsel, Chief Strategy Officer, Other
• What is your target window to have an externally licensed solution in place? Options: Within 3 months, 3 to 6 months, 6 to 12 months, Longer than 12 months, Unsure
• What single measurable outcome from a licensing engagement would make your leadership choose license over build immediately? Options: Shorter time to market (months), Lower projected development cost, Clear patent coverage for target features, Access to inventor expertise, Ability to form a startup partnership

How this risk shows up in your delivery and budget

• What hidden costs or schedule risks from an internal build do your leadership teams tend to underestimate?
• Walk me through the last time your team tried to develop a foundational platform feature in-house, what ran over budget or time, and why.
• Which technical unknowns in this area would require external IP or inventor cooperation to resolve before productization? Options: Core algorithm claims, Materials/process details, Scale-up data, Interfacing with existing systems, Regulatory validation
• How many full time engineering years do you estimate are needed to reach the same readiness a license could provide? Options: Less than 1 FTE-year, 1 to 3 FTE-years, 3 to 5 FTE-years, More than 5 FTE-years, Unsure
• If those internal estimates are realistic, what immediate impact would that have on your product schedule or launch budget?
• What single technical or budget threshold would make your team stop building internally and pursue a license without additional internal review?

Who must sign off and who can stall it

• List the internal roles that would block or approve a licensing deal if they are not engaged early enough. Options: R&D leadership, Product management, Procurement, Legal, Finance, Business development, Board/Investors
• Identify the person who would own the pilot internally and estimate how many hours per week they can commit to inventor calls and review tasks.
• Which external advisors or partners, for example venture partners or strategic customers, need to be consulted before a decision is final? Options: Existing lead investor, Strategic customer, Industry advisor, None, Other
• When key faculty cooperation is required, what steps will your team take to secure their time and responsiveness?
• Who in your procurement or legal group is typically the final contract signer and how long does their review usually take? Options: Less than 2 weeks, 2 to 4 weeks, 1 to 2 months, Longer than 2 months, Unsure

Where university rules could stop us

• Identify the specific university policy provisions or IP rules that, if present, would prevent your team from accepting a license.
• Are there ownership claims, royalty floors, or field-of-use restrictions you have encountered that made past deals uneconomical for your business? Options: Royalty too high, Exclusive restrictions, Field limitations, Equity requirements, Other, None experienced
• How long does your internal governance or compliance review take when a contract involves external academic IP? Options: Less than 2 weeks, 2 to 4 weeks, 1 to 2 months, Longer than 2 months, Unsure
• List the university approvals you expect would be required before a pilot can begin for your team. Options: Technology transfer signoff, Faculty consent, Sponsored research clearance, Export control check, Other
• Name the one policy or restriction that, if it exists, would immediately stop this deal for your team.

The other options on the table

• What set of choices are you actively evaluating right now, including internal build, incumbent vendors, or early-stage startups?
• Name any incumbent providers or internal programs you already have a relationship with and what keeps you with them today.
• Has anyone on your team proposed solving this without an outside partner, and if so what was their plan? Options: Yes, full internal build, Yes, hybrid internal/external, No external plan proposed, Unsure
• For each alternative you mentioned, what condition would have to be true for your team to stay with that option rather than change?
• If our pilot meets the agreed metrics, what single internal obstacle would still prevent you from signing a license quickly?

Operational readiness and gating questions

• What systems, datasets, or faculty commitments are currently missing that would prevent a pilot from starting within eight weeks?
• How many inventors will the pilot require access to, and how accessible are their lab notebooks, raw data, and contact details? Options: 1 inventor, fully accessible, 2-3 inventors, accessible with notice, 4+ inventors, limited access, Data not centralized, Unsure
• Confirm the owner of the data and any confidentiality or export restrictions your team expects will apply.
• Are APIs, lab databases, or other research systems required for evaluation accessible to an external partner, and who manages those systems? Options: Accessible and managed internally, Accessible with NDAs, Not accessible, Managed by third party, Unsure
• What internal roles can commit to the pilot immediately, for example a product engineer or legal reviewer, and how many hours per week can each commit?
• Name the one readiness gap that would force us to delay or cancel the pilot for your team.

How you will judge the pilot, and deal accelerators

• If the pilot delivers the targets you need, what would make you sign a license that same week?
• What specific metrics will prove to your leadership this technology reduces time to market or development cost for your roadmap? Options: Months shaved from roadmap, Estimated cost reduction, Number of claims covering core features, Identified commercial partners, Positive inventor engagement
• How will your team evaluate patent strength and freedom to operate as part of the pilot report? Options: Independent FTO study, Patent landscape summary, Claim coverage mapped to features, No formal patent review, Other
• Provide the primary approvers for the pilot report and the minimum endorsement each approver requires to proceed.
• If procurement or legal could still say no after a successful pilot, what reason would they give?

Timeline, budget, and commercial preferences

• How much budget has your team set aside to acquire external IP or pay licensing fees in the next 12 months? Options: Under $50k, $50k to $250k, $250k to $1M, Over $1M, No dedicated budget
• What internal owner controls that budget and what approval level is required to spend it? Options: R&D budget holder, Procurement, Strategic initiatives fund, CFO approval, Other
• Which commercial model do you prefer if the pilot succeeds, exclusive license, field-limited license, option-to-license, or equity arrangement? Options: Exclusive license, Field-limited license, Option-to-license, Equity stake, Unsure, need guidance
• How quickly can your team commit to starting a three to six month pilot once terms and readiness are confirmed? Options: Immediately, Within 2 weeks, Within 1 month, Longer than 1 month, Unsure
• If a licensing proposal includes a minimum term or royalty, what threshold would make the economics unacceptable for your product plan?

Clear next steps and commitment signals

• What would make your team move from evaluation to a firm commitment within four weeks?
• Point to the internal milestone or event that will trigger your formal go or no-go decision. Options: Budget cycle end, Product roadmap review, Board meeting, Customer pilot, Other
• Provide the primary contact name, role, and best email for scheduling inventor interviews and sharing documents.
• By when can your team deliver the first set of five inventions for an initial pilot assessment? Options: Within 2 weeks, Within 4 weeks, Within 6 weeks, Longer than 6 weeks, Unsure
• Are there any absolute deal breakers or non-starters we should surface before drafting a pilot agreement? Options: No equity allowed, No field exclusivity, Maximum royalty cap, Faculty time commitment required, Other, None
• If everything aligns on readiness and metrics, can your team sign a letter of intent within two weeks to lock timelines and access? Options: Yes, Maybe, need internal approval, No

• Solution Experience Session

• Confirm the current state and its cost to your team
• You confirm the restated current state and the quantified cost to roadmap, development budget, or market timing.
• Deliver three evaluated invention summaries with recommended patent strategy and a staged outreach plan within 10 business days.
• You confirm that the demonstrated evaluation and patent strategy materially shortens time to a license‑decision for the sample inventions.
• Map your portfolio context and decision criteria
• Provide five candidate invention disclosures and your decision criteria spreadsheet for pilot selection within 5 business days.
• Run a portfolio scenario end‑to‑end
• You agree on the remaining evidence needed and accept the pilot acceptance criteria to proceed to a time‑boxed assessment.
• Confirm the pilot acceptance criteria and target timeline in writing after this session.
• Translate how this shortens time and reduces risk
• Validate the future state

• Solution Experience Session
• Solution Experience Deck
• Solution Brief

• meeting
• slides
• document

• Draft and file patent applications
• Manage patent prosecution and office actions
• Maintain patent docketing, annuities, and payments
• Prepare confidential technology disclosure and marketing package
• Execute targeted licensee outreach campaigns
• Negotiate and execute license agreements
• Structure startup license terms and founder equity arrangements
• Assemble investor and licensee due-diligence data room
• Draft and execute NDAs and material transfer agreements
• Perform freedom-to-operate and prior-art searches
• Administer royalty accounting, invoicing, and reporting
• Run 5–10 invention pilot commercialization program
• Facilitate inventor technical validation and industry collaboration

Draft and file patent applications

• Do you have existing invention disclosure IDs and completed disclosure forms for the inventions to be filed? Options: Yes, No, Partial list available
• How many provisional or nonprovisional patent filings do you expect to submit in the next 12 months? Options: 1-3, 4-10, 11-25, 26+
• Which filing routes do you want considered for each disclosure (provisional, US nonprovisional, Patent Cooperation Treaty (PCT))? Options: Provisional, US nonprovisional, PCT (international), Undecided
• Who will provide the experimental data, figures, and technical write-ups required for the specification and drawings? Options: Lead inventor, Department research admin, External contractor, Not assigned yet
• What deadlines tied to conferences, grant reports, or public disclosures require filings within a specific timeframe? Options: Within 2 weeks, 2-6 weeks, 6-12 weeks, No firm deadline

Manage patent prosecution and office actions

• How many active office actions across your portfolio require responses within the next 6 months? Options: None, 1-3, 4-10, 11+
• Which Cooperative Patent Classification (CPC) groups or technical art units are most common for the inventions under prosecution?
• Who will review and approve proposed claim amendments and draft responses to office actions? Options: Lead inventor, In-house counsel, External patent counsel, No reviewer assigned
• What turnaround time in business days do you require for draft office action responses to be delivered for internal review? Options: 5-10 business days, 11-20 business days, 21-30 business days, Custom
• Are there prosecution budget caps per office-action response or per family that we must not exceed? Options: Yes, No

Maintain patent docketing, annuities, and payments

• Do you currently use a patent docketing system that we must integrate with for deadlines, annuities, and reminders? Options: Yes - internal system, Yes - external provider, No
• How many patent families require annuity tracking across multiple jurisdictions? Options: 1-10, 11-50, 51-200, 200+
• Which currencies and payment channels must be supported for foreign annuities and attorney fees? Options: USD, EUR, GBP, Local currency (specify)
• Who is authorized within your organization to approve annuity payments and sign vendor invoices? Options: Finance contact, Authorized signer (title), Department administrator, Not yet assigned
• What confirmation SLA do you expect after annuity payment (e.g., receipt uploaded to IP management platform within X days)? Options: Payment posted and receipt in 3 business days, 3-7 business days, Custom

Prepare confidential technology disclosure and marketing package

• Which invention disclosure template do you want standardized for external marketing packages (one-page summary, five-slide brief, technical appendix)? Options: 1-page summary, 3-slide brief, 5-slide brief + appendix, Custom
• What experimental artifacts must be included in each confidential package (figures, assay protocols, raw data files, replicates)? Options: Figures and key graphs, Assay protocols, Raw data files, All of the above
• Who will approve redactions of sensitive method details before sharing the confidential package externally? Options: Lead inventor, Department chair, Authorized reviewer, No approver assigned
• Are there sponsor or funder constraints (e.g., federal grant clauses, export control) that limit material you can include in marketing packages? Options: Yes, No, Unsure - need review
• What versioning policy should apply to confidential packages tied to executed NDAs (e.g., v1.0, v1.1 with dates)? Options: Versioned with dates, Single master copy, Custom policy

Execute targeted licensee outreach campaigns

• How many target companies should each campaign reach per invention or technology cluster? Options: 10-25, 26-50, 51-100, 100+
• Which industry segments and application areas should outreach prioritize (for example pharmaceuticals/biologics, medical devices, diagnostics, materials)? Options: Pharmaceuticals / Biologics, Medical devices, Diagnostics, Materials / Chemicals, Energy / CleanTech, Other
• Which outreach assets will you authorize for initial contact (confidential package, inventor intro call, published paper, prototype data)? Options: Confidential package, Intro call with inventor, Published paper link, Prototype or demo data
• Who should coordinate scheduling of introductory calls between company contacts and inventors? Options: Your BD lead, Inventor, Program coordinator, No coordinator assigned
• What tracking do you require for outreach results (CRM entry, outreach log, meeting outcomes) and do you need integration into your current CRM? Options: CRM integration required, Manual log only, Both CRM and manual log, Not required

Negotiate and execute license agreements

• Which license model(s) should be considered during negotiation (exclusive, nonexclusive, field-limited, option-to-license)? Options: Exclusive, Nonexclusive, Field-limited exclusive, Option-to-license
• What royalty structure ranges are acceptable as a starting point (fixed fee, percent of product sales, tiered royalties)? Options: Fixed fee + royalty, Percent of product sales (negotiable), Tiered royalty schedule, Revenue share / milestone heavy
• Who in your organization is the authorized signer for executed license agreements or who will be designated prior to execution? Options: VP R&D, CFO, Authorized signer to be assigned, In-house counsel
• What acceptance criteria will confirm a negotiated license is fully executed and ready for commercialization (examples: signed agreement, data access granted, initial payment received)?
• Are there specific limitations you require in indemnity, liability, or faculty cooperation clauses (for example limits on warranty or obligations to provide inventor support)? Options: Yes, No

Structure startup license terms and founder equity arrangements

• Which type of license recipients do you expect (faculty-founded startups, external startups, or both)? Options: Faculty-founded startups, External startups, Both
• What founder equity and vesting patterns are acceptable to the institution (for example 4-year vesting with 1-year cliff)? Options: 4 years with 1-year cliff, 3 years, Custom / negotiable
• How should intellectual property assignment and founder contribution records be documented for startup diligence (signed assignment, inventor declarations, lab notebooks)? Options: Signed assignment records, Inventor declarations, Lab notebook excerpts, All of the above
• Who will manage founder equity cap decisions and sign-off on founder-friendly provisions? Options: Technology transfer lead, In-house counsel, Department chair, Not yet assigned
• Do you want milestone-linked royalty or equity adjustments tied to fundraising events in term sheets? Options: Yes, No, Undecided - discuss

Assemble investor and licensee due-diligence data room

• List the document categories that must be present in the data room (patent PDFs, prosecution history, inventor CVs, sponsored research agreements, MTAs, grant funding records). Options: Patent PDFs, Prosecution history, Inventor CVs, Sponsored research agreements, MTAs, Grant funding records
• Which secure platform should host the data room (your secure folder, investor virtual data room, or a platform to be selected)? Options: Your secure folder, Investor VDR, Platform to be selected, Undecided
• What access controls and reviewer policies do you require (watermarking, no-download, timed expiration, reviewer NDAs)? Options: Watermarking, Download disabled, Timed expiration, Reviewer NDA required
• Who will prepare and certify inventor CVs, conflict-of-interest disclosures, and chain-of-title documents for upload? Options: Inventors, Department admin, In-house counsel, External counsel
• What evidence will you accept to confirm the data room is complete for investor or licensee diligence (all patent PDFs and prosecution histories uploaded, signed MTAs, inventor CVs)?

Draft and execute NDAs and material transfer agreements

• Do you use a standard NDA template or do you require custom NDA variants for different partner types (industry, academic, government)? Options: Standard NDA template, Custom NDA templates needed, No NDA template in use
• Which fixed terms must appear in all NDAs you accept (confidentiality term length, return/destroy clauses, permitted disclosures to funders)?
• Which material types require a Material Transfer Agreement (MTA) before release (cell lines, plasmids, antibodies, prototype devices)? Options: Cell lines, Plasmids, Antibodies, Prototype devices, All of the above
• Who approves MTA terms and shipping for physical materials and who signs shipment manifests? Options: Lead inventor, Department admin, Authorized signer, No approver assigned
• What SLA do you require for NDA turnaround from receipt to signed (for example signed within X business days)? Options: 3 business days, 5-7 business days, Custom

Perform freedom-to-operate and prior-art searches

• Which jurisdictions must be included in freedom-to-operate (FTO) clearance (United States, European Patent Office, Japan, China, other)? Options: United States, European Patent Office / EU, Japan, China, Other
• How many claims or patent families should each FTO analysis cover per report? Options: 1-3 claims/families, 4-10, 10+
• Which search depth do you expect: patent literature only; patents plus non-patent literature such as conference abstracts and theses; or comprehensive including non-English sources? Options: Patents only, Patents + non-patent literature, Comprehensive including non-English sources
• Who in your organization will accept FTO risk findings and sign off on go/no-go commercialization decisions based on the opinion? Options: Head of R&D, In-house counsel, Authorized program owner, Not decided
• What timeline do you require for an initial FTO report per invention (for example 2 weeks, 4 weeks)? Options: 2 weeks, 4 weeks, 6+ weeks, Custom

Administer royalty accounting, invoicing, and reporting

• Which invoicing frequency should be used for royalty reporting (quarterly, semi-annual, annual)? Options: Quarterly, Semi-annual, Annual
• Do you require gross-to-net calculations, reserves, and audit support in royalty accounting? Options: Yes, No
• Who should receive royalty invoices and who is the finance contact responsible for remittance? Options: Finance director, Accounts payable team, Authorized signer, Contact to be provided
• Which report formats do you require for royalty statements (CSV for import, PDF summary, integration with finance system) ? Options: CSV export, PDF summary, Integration to finance system, Other
• What remittance SLA do you expect after invoicing (for example payment within 30 days of invoice)? Options: 30 days, 45 days, Custom

Run 5–10 invention pilot commercialization program

• List the 5–10 inventions you propose for the pilot by disclosure ID or short title.
• What timeline do you expect for the pilot (for example portfolio audit in 6-8 weeks followed by a 12-week outreach phase)? Options: 6-8 weeks audit + 12-week outreach, 8-12 weeks audit, Custom timeline
• What measurable acceptance criteria will confirm pilot success (examples: number of validated inventions, number of qualified licensee conversations, NDAs executed)?
• What inventor time commitments and internal resources can you allocate to the pilot (hours per week per inventor)? Options: <4 hours/week, 4-8 hours/week, 8-16 hours/week, 16+ hours/week
• Which activities are explicitly out of scope for the pilot (bench experiments, regulatory filings, paid clinical studies, long-term product development)? Options: Bench experiments, Regulatory submissions, Clinical studies, Long-term product development

• current_state
• desired_state
• decision_readiness
• stakeholders
• gaps
• success_criteria
• desired_state
• decision_readiness
• current_state
• success_criteria
• gaps
• stakeholders
• desired_state
• success_criteria
• stakeholders
• gaps
• current_state
• decision_readiness
• decision_readiness
• decision_readiness
• decision_readiness
• decision_readiness

• Master Services Agreement (MSA)
• Program Statement of Work (SOW)
• Commercial Term Sheet
• Template License Agreement (form)
• Data Sharing & Access Agreement
• Faculty Cooperation Agreement
• Program Governance Charter
• Regulatory Compliance Addendum (conditional)

• Go-live Health Check (weeks 1-4)
• First Measurement Review (weeks 4-10)
• Acceptance Gate Review (around day 90)
• Quarterly Commercialization Review

• Circulate the quarterly metrics snapshot and the next quarter's measurement plan to stakeholders.
• Produce a documented acceptance decision with pass/fail recorded for each Engagement Scope criterion.
• Capture a remediation plan and timeline for any failed criteria that require additional work.
• Circulate an acceptance decision record signed by the named buyer signatory or their authorized delegate.
• Publish the formal acceptance record with pass/fail status for each Engagement Scope criterion.
• Document remediation tasks for failed criteria with target completion dates and required verification evidence.
• Archive the acceptance meeting materials and link them to the program record for auditability.
• Commercialization outcomes vs targets
• Confirm whether quarterly licensing outcomes and disclosure-to-license timing are on target and capture any deviations.
• Prioritize enhancement requests and create a timebound backlog for resolution.
• Ensure persistent operational blockers have documented remediation plans and timelines.
• Publish the prioritized enhancement backlog with expected delivery windows.
• Open remediation tickets for any persistent operational blockers with target resolution dates.
• Re-confirm success criteria and owners
• Confirm deployment completed and data access validated against the targets recorded in Engagement Scope.
• Document a prioritized list of go-live blockers with remediation actions and target dates.
• Verify incumbent system is decommissioned or retained read-only with migration or archive plan in place.
• Publish go-live issue log with remediation actions and target completion dates.
• Complete migration or archival of legacy tech transfer records and document retention location.
• Confirm and record named owners for each measurable acceptance criterion in Engagement Scope.
• Present first-period outcome data
• Determine whether the number of inventions in active licensing discussions and outreach response rate are trending toward Engagement Scope targets.
• Agree a prioritized set of corrective actions with target resolution dates to address identified shortfalls.
• Confirm readiness timeline to the acceptance gate meeting around day 90.
• Document agreed corrective actions with completion dates and required evidence for verification.
• Collect and circulate the next-period data sources and definitions for the metrics presented.
• Schedule detailed review sessions for any technical or faculty-engagement blockers identified.
• Restate acceptance criteria and numeric targets
• Deployment and data access validation
• Present outcome data against each criterion
• Open issues, operational tickets, and faculty engagement
• Root-cause diagnosis for any gaps
• Enhancement request backlog and prioritization
• Agree corrective actions and timelines
• Early adoption signals and usage patterns
• Document pass or fail per criterion and capture decision
• Incumbent wind-down status update
• Agree remediation plan for any failed criteria
• Confirm next quarter measurement focus and data cadence
• Open issues and remediation assignments
• Incumbent wind-down confirmation